- Home
- OCSL vs PRAX Comparison
OCSL vs PRAX Comparison
Compare OCSL & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OCSL
- PRAX
- Stock Information
- Founded
- OCSL 2007
- PRAX 2015
- Country
- OCSL United States
- PRAX United States
- Employees
- OCSL N/A
- PRAX N/A
- Industry
- OCSL Finance: Consumer Services
- PRAX Biotechnology: Pharmaceutical Preparations
- Sector
- OCSL Finance
- PRAX Health Care
- Exchange
- OCSL Nasdaq
- PRAX Nasdaq
- Market Cap
- OCSL 1.3B
- PRAX 1.4B
- IPO Year
- OCSL 2008
- PRAX 2020
- Fundamental
- Price
- OCSL $16.03
- PRAX $74.49
- Analyst Decision
- OCSL Hold
- PRAX Strong Buy
- Analyst Count
- OCSL 7
- PRAX 9
- Target Price
- OCSL $16.75
- PRAX $149.00
- AVG Volume (30 Days)
- OCSL 670.7K
- PRAX 388.8K
- Earning Date
- OCSL 02-04-2025
- PRAX 03-04-2025
- Dividend Yield
- OCSL 11.73%
- PRAX N/A
- EPS Growth
- OCSL N/A
- PRAX N/A
- EPS
- OCSL 0.67
- PRAX N/A
- Revenue
- OCSL $370,327,000.00
- PRAX $1,605,000.00
- Revenue This Year
- OCSL N/A
- PRAX N/A
- Revenue Next Year
- OCSL N/A
- PRAX N/A
- P/E Ratio
- OCSL $23.93
- PRAX N/A
- Revenue Growth
- OCSL N/A
- PRAX N/A
- 52 Week Low
- OCSL $14.89
- PRAX $33.01
- 52 Week High
- OCSL $20.43
- PRAX $91.83
- Technical
- Relative Strength Index (RSI)
- OCSL 59.53
- PRAX 42.80
- Support Level
- OCSL $15.33
- PRAX $76.00
- Resistance Level
- OCSL $15.88
- PRAX $91.83
- Average True Range (ATR)
- OCSL 0.23
- PRAX 6.29
- MACD
- OCSL 0.04
- PRAX -1.10
- Stochastic Oscillator
- OCSL 88.78
- PRAX 2.42
About OCSL Oaktree Specialty Lending Corporation
Oaktree Specialty Lending Corp is a specialty finance company. The company provides lending services and invests in small and mid-sized companies. The company's investment objective is to maximize its portfolio's total return by generating current income from debt investments, and to a lesser extent, capital appreciation from equity investments. The company provides customized, one-stop credit solutions to companies with limited access to public or syndicated capital markets.
About PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The firm's pipeline covers PRAX-114, for the treatment of a broad range of patients suffering from major depressive disorder and post-traumatic stress disorder; PRAX-944, for the treatment of Essential Tremor and Parkinson's Disease; PRAX-562, and PRAX-222, among others.